Clinical trial
Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound
NCT01067820 is registered in ClinicalTrials.gov with Resverlogix Corp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound
- Lead sponsor
- Resverlogix Corp
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2011
- Completion date
- June 30, 2013
- Enrollment
- 324 (actual)
- Sites
- 58
Conditions
As the registry lists them; a condition with its own page is linked.